blu-5937 gsk：Health Technology Briefing June 2024
Health Technology Briefing June 2024
Coughcountof≥10perhour.Intervention(s).BLU-5937(FourescalatingdosesofBLU-5937(25,50,100,200mg)administeredtwicedailyoverthecourseof ...。其他文章還包含有：「Pipeline」、「https」、「Evaluationoftheeffectofrifampinandrabeprazoleon...」、「临床失败后，适应症一再缩减，这药20亿美元买下亏不亏？」、「葛蘭素史克(GSK.US)慢性咳嗽療法在中國啓動3期臨床」、「A52」、「camlipixant(GSK5464714)GSK」、「q1-202...
查看更多 離開網站
Pipeline
https://gskusmedicalaffairs.co
P2X3 Antagonist (camlipixant [BLU-5937]). CALM-1: A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults with Refractory Chronic Cough. Go to ...
https
https://classic.clinicaltrials
沒有這個頁面的資訊。
Evaluation of the effect of rifampin and rabeprazole on ...
https://www.gsk-studyregister.
This is a phase 1, 2-part, open-label, fixed-sequence study evaluating the effect of rifampin (part 1) and rabeprazole (part 2) on the pharmacokinetics of a ...
临床失败后，适应症一再缩减，这药20亿美元买下亏不亏？
http://www.phirda.com
GSK表示，这笔收购是奔着Bellus在临床3期阶段的“止咳药”Camlipixant (BLU-5937)而来。这款让GSK分外眼馋的止咳药，曾经也险些葬送Bellus。BLU-5937 ...
葛蘭素史克(GSK.US)慢性咳嗽療法在中國啓動3期臨床
https://www.moomoo.com
... BLU-5937治療難治性慢性咳嗽(包括不明原因的慢性咳嗽)的安全性和有效性。公開資料顯示，BLU-5937(camlipixant)是一款選擇性口服P2X3受體拮抗劑。2023 ...
A 52
https://ctv.veeva.com
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
camlipixant (GSK5464714) GSK
https://delta.larvol.com
Camlipixant reduces burden of cough-related urinary incontinence in patients with refractory chronic cough in post-hoc analysis of a Phase 2b trial.
q1-2024
https://www.gsk.com
Camlipixant (BLU-5937) is an investigational, highly selective oral P2X3 antagonist currently in development for first-line treatment of ...
GSK约20亿美元收购公司所得！P2X3受体拮抗剂在中国获批 ...
https://finance.sina.cn
BLU-5937正是一款具有高度选择性的强效P2X3受体拮抗剂。临床数据显示，通过选择性抑制P2X3受体，该产品可以降低患有难治性慢性咳嗽患者的咳嗽频率，且产生 ...